质母细胞瘤和其他恶性质母细胞瘤:临床综述
Antonio Omuro1, Lisa M DeAngelis
1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York.
JAMA
|November 7, 2013
概括
恶性质瘤是具有不良预后的侵袭性脑瘤. 目前的治疗方法,如放射治疗和temozolomide可以提高生存率,但最佳管理需要多学科的方法.
科学领域:
- 神经瘤学神经瘤学
- 癌症研究 癌症研究
- 大脑瘤的临床管理.
背景情况:
- 质母细胞瘤和恶性质母细胞瘤是主要的大脑瘤,发病率高,预后不佳.
- 这些瘤显著影响患者的生活质量.
研究的目的:
- 审查恶性质瘤的临床管理.
- 讨论风险因素,诊断挑战,症状控制,治疗和并发症.
主要方法:
- 使用相关关键词从2000年至2013年的PubMed文献搜索.
- 使用美国心脏协会分类系统对证据进行分级.
主要成果:
- 辐射和遗传综合征是已知的危险因素.
- 用temozolomide进行的放射治疗使质母细胞瘤的2年生存率提高到27%,但预后仍然很差.
- 贝瓦西祖马布显示出潜力;三级瘤需要进一步的研究和临床试验.
结论:
- 质母细胞瘤治疗具有挑战性,尽管选择正在改善.
- 有效的管理需要一个多学科的战略.
- 了解和管理疾病和治疗并发症至关重要.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...